Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Roth Capital Reiterates Neutral Rating On Corbus Pharmaceuticals Following Negative Phase 3 Trial In Dermatomyositis, $1.79 Price Target.


Benzinga | Jun 25, 2021 10:21AM EDT

Roth Capital Reiterates Neutral Rating On Corbus Pharmaceuticals Following Negative Phase 3 Trial In Dermatomyositis, $1.79 Price Target.






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC